Essential structural profile of a dual functional inhibitor against cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX): molecular docking and 3D-QSAR analyses on DHDMBF analogues
- PMID: 16458008
- DOI: 10.1016/j.bmc.2005.12.062
Essential structural profile of a dual functional inhibitor against cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX): molecular docking and 3D-QSAR analyses on DHDMBF analogues
Abstract
It is recently proposed that compounds with equal capabilities of inhibiting COX and 5-LOX, both are key enzymes involved in the arachidonic acid (AA) cascade, are expected to be safer non-steroidal anti-inflammatory drugs (NSAIDs). To dig out helpful information in designing dual functional inhibitors against the two enzymes, homology modeling, molecular dynamics (MD) simulations, automated docking, and 3D-QSAR analyses were performed in this study on 21 COX-2/5-LOX dual inhibitors, namely, 7-tert-butyl-2,3-dihydro-3,3-dimethylbenzofuran (DHDMBF) analogues. A 3D-model of 5-LOX was built based on the high-resolution X-ray structure of rabbit reticulocyte 15-lipoxygenase. Molecular docking was then applied to locate the binding orientations and conformations of DHDMBF analogues with COX-2 and 5-LOX, respectively, leading to highly predictive CoMFA models constructed on the basis of the binding conformations with q2 values of 0.782 and 0.634 for COX-2 and 5-LOX, respectively. In addition, CoMFA field distributions were found in good agreement with the structural characteristics of the corresponding binding sites. Both the docking simulations and QSAR analyses suggest that new potent dual inhibitors should share a structural feature with a moderately bulky group at R2 position and a rather negatively charged group around the position of the carbonyl group of DHDMBFs. Therefore, the final 3D-QSAR models and the information of the inhibitor-enzyme interaction should be useful in developing new NSAIDs as anti-inflammation drugs with favorable safety profile.
Similar articles
-
Rationalization of physicochemical characters of 1,5-diarylpyrazole analogs as dual (COX-2/LOX-5) inhibitors: a QSAR approach.J Pharm Biomed Anal. 2006 Sep 18;42(2):283-9. doi: 10.1016/j.jpba.2006.04.020. Epub 2006 Jun 14. J Pharm Biomed Anal. 2006. PMID: 16781106
-
Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.J Med Chem. 2006 Mar 9;49(5):1668-83. doi: 10.1021/jm0510474. J Med Chem. 2006. PMID: 16509583
-
Enzyme selectivity of new cyclooxygenase-2/5 lipoxygenase inhibitors using molecular modeling approach.Indian J Biochem Biophys. 2000 Apr;37(2):86-96. Indian J Biochem Biophys. 2000. PMID: 10983419
-
Synthetically-tailored and nature-derived dual COX-2/5-LOX inhibitors: Structural aspects and SAR.Eur J Med Chem. 2021 Dec 5;225:113804. doi: 10.1016/j.ejmech.2021.113804. Epub 2021 Aug 27. Eur J Med Chem. 2021. PMID: 34479036 Review.
-
Dual COX-2/15-LOX inhibitors: A new avenue in the prevention of cancer.Eur J Med Chem. 2023 Dec 5;261:115866. doi: 10.1016/j.ejmech.2023.115866. Epub 2023 Oct 13. Eur J Med Chem. 2023. PMID: 37862815 Review.
Cited by
-
Computational Analysis of LOX1 Inhibition Identifies Descriptors Responsible for Binding Selectivity.ACS Omega. 2018 Feb 28;3(2):2261-2272. doi: 10.1021/acsomega.7b01622. Epub 2018 Feb 26. ACS Omega. 2018. PMID: 30023828 Free PMC article.
-
Effect of 5-LOX/COX-2 common inhibitor DHDMBF30 on pancreatic cancer cell Capan2.World J Gastroenterol. 2008 Apr 28;14(16):2494-500. doi: 10.3748/wjg.14.2494. World J Gastroenterol. 2008. PMID: 18442195 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials